SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥142.86-CN¥0.03 (-0.02%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.69% below the high.
Loading market information…
HKSE · 2565.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 05:58 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
PegBio Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 93.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
PegBio Co., Ltd.’s next earnings report is currently expected on Mar 23, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow PegBio Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia. Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity. PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
CN¥142.86-CN¥0.03 (-0.02%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.69% below the high.
CN¥48.70+CN¥0.08 (+0.16%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.95% below the high.
HK$51.05+HK$0.40 (+0.79%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.0% below the high.
CN¥182.95+CN¥3.95 (+2.21%)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.5% below the high.
HK$42.46-HK$0.54 (-1.26%)
Suzhou Ribo Life Science Co’s quoted price sits in the lower half of its reported 52-week range, 55.68% below the high.
HK$4.96-HK$0.26 (-4.89%)
Ascletis Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.03% below the high.
HK$5.68+HK$0.04 (+0.71%)
Laekna, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.69% below the high.
HK$2.22-HK$0.05 (-1.99%)
Hua Medicine (Shanghai) Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.78% below the high.
